Form 4 for OKUR OnKure Therapeutics, Inc.
Accepted 2021-11-15 00:00:00 ET · period of report 2021-11-12 · accession 0001209191-21-064587 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-15 | 2021-11-12 | OKUR | Hall Ashley | Chief Development Off | A - Grant | $0.00 | +30.0K | 30.0K | New | $0 |
| D | 2021-11-15 | 2021-11-12 | OKUR | Hall Ashley | Chief Development Off | A - Grant | $0.00 | +180.0K | 180.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-12 | A | A | 30,000 | $0.00 | 30,000 | D | — | — | (F1) Represents a restricted stock unit award. |
| 2 | Derivative | Stock Option (right to buy) | 2021-11-12 | A | A | 180,000 | $0.00 | 180,000 | D | $8.85 · — to 2031-11-11 | 180,000 Common Stock | (F2) 1/4 of the shares subject to the stock option vest and become exercisable on October 11, 2022, and the remaining shares vest in equal monthly installments over the subsequent 36 months. |